The anticancer effects of Vitamin D and omega-3 PUFAs in combination via cod-liver oil: One plus one may equal more than two

Medical Hypotheses

Volumn 77, Issue 3, 2011, Pages 326-332

  Dyck, Martin C ^a   Ma, David WL ^a   Meckling, Kelly Anne ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; COD LIVER OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; RETINOID X RECEPTOR; VITAMIN D; VITAMIN D RECEPTOR;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALCIUM ABSORPTION; CANCER PREVENTION; CAVEOLA; DRUG MECHANISM; HUMAN; IMMUNE FUNCTION TEST; NONHUMAN; VITAMIN SUPPLEMENTATION;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL PROLIFERATION; COD LIVER OIL; FATTY ACIDS, OMEGA-3; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; VITAMIN D;

EID: 80051818563     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2011.05.006     Document Type: Article

References (120)

1. The World Health Report 1997, WHO, World Health Organization, WHO, Geneva.
2. Giovannucci E., Willett W.C. Dietary factors and risk of colon cancer. Ann Rev Med 1994, 26:443-452.
3. Stripp C., Overvad K., Christensen J., Thomsen B.L., Olsen A., Moller S., et al. Fish intake is positively associated with breast cancer incidence rate. J Nutr 2003, 33:3664-3669.
4. Terry P.D., Terry J.B., Rohan T.E. Long-chain (n-3) fatty acid intake and risk of cancers of the breast and the prostate: recent epidemiological studies, biological mechanisms, and directions for future research. J Nutr 2004, 134:3412S-3420S.
5. Schley P.D., Brindley D.N., Field C.J. N-3 PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J Nutr 2007, 137:548-553.
6. Berquin I.M., Min Y., Wu R., et al. Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J Clin Invest 2007, 117:1866-1875.
7. Petrik M.B., McEntee M.F., Johnson B.T., Obukowicz M.G., Whelan J. Highly unsaturated (n-3) fatty acids, but not α-linoleic, or γ-linolenic acids, reduce tumorigenesis in Apc min/+ mice. J Nutr 2000, 130:2434-2443.
8. Ng Y., Barhoumi R., Tjalkens R.B., et al. The role of docosahexaenoic acid in mediating mitochondrial membrane lipid oxidation and apoptosis in colonocytes. Carcinogenesis 2005, 26:1914-1921.
9. Chapkin R.S., Davidson L.A., Ly L., Weeks B.R., Lupton J.R., McMurray D.N. Immunomodulatory effects of (n-3) fatty acids: putative link to inflammation and colon cancer. J Nutr 2007, 137:200S-204S.
10. Collett E.D., Davidson L.A., Lupton J.R., Chapkin R.S. Dietary fish oil reduces colon cancer risk. Curr Organic Chem 2000, 4:1157-1168.
11. Davidson L.A., Nguyen D.V., Hokanson R.M., et al. Chemopreventive n-3 polyunsaturated fatty acids reprogram genetic signatures during colon cancer initiation and progression in the rat. Cancer Res 2004, 64:6797-6804.
12. Cheng J., Ogawa K., Kuriki K., et al. Increased intake of n-3 polyunsaturated fatty acids elevates the level of apoptosis in the normal sigmoid colon of patients polypectomized for adenomas/tumors. Cancer Lett 2003, 193:17-24.
13. Geelen A., Schouten J.M., Kamphuis C., et al. Fish Consumption, n-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies. Am J Epidemiol 2007, 168:1116-1125.
14. Kobayashi M., Tsubono Y., Otani T., Hanaoka T., Sobue T., Tsugane S. Fish, long-chain n-3 polyunsaturated fatty acids, and risk of colorectal cancer in middle-aged Japanese: the JPHC study. Nutr Cancer 2004, 49:32-40.
15. Oh K., Willett W.C., Fuchs C.S., Giovannucci E. Dietary marine n-3 fatty acids in relation to risk of distal colorectal adenoma in women. Cancer Epidemiol Biomarkers Prev 2005, 14:835-841.
16. MacLean C.H., Newberry S.J., Mojica W.A., et al. Effects of omega-3 fatty acids on cancer risk: a systematic review. J Am Med Assoc 2006, 295:403-415.
17. Kojima M., Wakai K., Tokudome S., et al. Serum levels of polyunsaturated fatty acids and risk of colorectal cancer: a prospective study. Am J Epidemiol 2005, 161:462-471.
18. Caygill C.P., Hill M.J. Fish, n-3 fatty acids and human colorectal and breast cancer mortality. Eur J Cancer Prev 1995, 4:329-332.
19. Caygill C.P.J., Charland S.L., Lippin J.A. Fat, fish, fish oil, and cancer. Br J Cancer 1996, 74:159-164.
20. World Cancer Research Fund and American Institute for Cancer Research. Food, nutrition, and the prevention of cancer: a global perspective; 1997, p. 216.
21. Bougnoux P. N-3 polyunsaturated fatty acids and cancer. Curr Opin Clin Nutr Metab Care 1999, 2:121-126.
22. Cave W.T. Omega-3 polyunsaturated fatty acids in rodent models of 2 breast cancer. Breast Can Res Treat 1996, 46:239-246.
23. Larsson S.C., Kumlin M., Ingelman-Sundberg M., Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004, 79:935-945.
24. Welsh J. Vitamin D and breast cancer: insights from animal models. J Nutr 2004, 80(Suppl):1721S-1724S.
25. Nonn L., Peng L., Feldman D., Peehl D.M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate cancer prevention by vitamin D. Cancer Res 2006, 66:4516-4524.
26. Stewart L.V., Lyles B., Lin M.F., Weigel N.L. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol 2005, 97:37-46.
27. Jemenez-Lara A.M. Colorectal cancer: potential therapeutic benefits of vitamin D. Int J Biochem Cell Biol 2007, 39:672-677.
28. Aguilera O., Pena C., Garcia J.M., et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha, 25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 2007, 28:1877-1884.
29. Parise R.A., Egorin M.J., Kanterewicz B., et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 2006, 119:1819-1828.
30. Garland C.F., Gorham E.D., Mohr S.B., et al. Vitamin D and prevention of breast cancer: pooled analysis. J Steroid Biochem Mol Biol 2007, 103:708-711.
31. Bertone-Johnson E.R. Prospective studies of dietary vitamin D and breast cancer: more questions raised than answered. Nutr Rev 2000, 65:359-366.
32. Robien K., Cutler G.J., Lazovich D. Vitamin D intake and breast cancer risk in postmenopausal women: the Iowa Women's Health Study. Cancer Causes Control 2007, 18:775-782.
33. Li H., Stampfer M.J., Hollis J.B., et al. A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Medicine 2007, 4:562-571.
34. Cross H.S., Bises G., Lechner D., Manhardt T., Kallay E. The vitamin D endocrine system of the gut-Its possible role in colorectal cancer prevention. J Steroid Biochem Mol Biol 2005, 97:121-128.
35. Porojnicu A., Robsahm T.E., Berg J.P., Moan J. Season of diagnosis is a predictor of cancer survival. Sun-induced vitamin D may be involved: a possible role of sun-induced Vitamin D. J Steroid Biochem Mol Biol 2007, 103:675-678.
36. Istfan N.W., Person K.S., Holick M.F., Chen T.C. 1 alpha, 25-dihydroxyvitamin D and fish oil synergistically inhibit G(1)/S-phase transition in prostate cancer cells. J Steroid Biochem Mol Biol 2007, 103:726-730.
37. Hong M.Y., Chapkin R.S., Barhoumi R., et al. Fish oil increases mitochondrial phospholipid unsaturation, upregulating reactive oxygen species and apoptosis in rat colonocytes. Carcinogenesis 2002, 23:919-1925.
38. Rajakumar K. Vitamin D, cod-liver oil, sunlight, and rickets: a historical perspective. Pediatrics 2003, 112:132-135.
39. Moser P. In cod we trust. Health 1993, 7:35.
40. Holich M.F. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006, 92:49-59.
41. Holt L.E. Let us give the Russians their due [letter]. Pediatrics 1963, 32:462.
42. Fomon S. Infant feeding in the 20th century: formula and beikost. J Nutr 2001, 131(2):409S-420S.
43. A dose of vitamin D history. Nature Struct Biol 2002;9(2):77.
44. Semba R.D. Vitamin A as " anti-infective" therapy, 1920-1940. J Nutr 1999, 129:783-791.
45. Merlino L. Vitamin D intake is inversely associated with rheumatoid arthritis: results from the Iowa Women's Health Study. Arthritis Rheum 2004, 50:72-77.
46. Patel S. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 2007, 56:2143-2149.
47. Geusens P., Wouters C., Nijs J., Jiang Y., Dequeker J. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis Rheum 1994, 37(6):824-829.
48. Ariza-Ariza R. Omega-3 fatty acids in rheumatoid arthritis: an overview. Semin Arthritis Rheum 1998, 27:366-370.
49. Galarraga B., Ho M., Youssef H.M., et al. Cod liver oil (n-3 fatty acids) as a non-steroidal anti-inflammatory drug sparing agent in rheumatoid arthritis. Rheumatol 2008, 10:1093-1098.
50. Kremer J.M., Lawrence D.A., Jubiz W., et al. Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis; Clinical and immunologic effects. Arthritis Rheum 1990, 33:810-820.
51. Welsh J., Wietzke J.A., Zinser G.M., Byrne B., Smith K., Nar-vaez C.J. Vitamin D-3 receptor as a target for breast cancer prevention. J Nutr 2003, 133(Suppl. 7):2425S-2433S.
52. Huang D.C., Papavasiliou V., Rhim J.S., Horst R.L., Kremer R. Targeted disruption of 25-hydroxyvitamin D3 1, 25-dihydroxyvitamin D3 suppresses growth and induces differention in an autocrine fashion. Mol Cancer Res 2002, 1:56-67.
53. Hsu J., Feldman D., McNeal J.E., Peehl D.M. Reduced 1-α hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3 -induced growth inhibition. Cancer Res 2001, 61:2852-2856.
54. Zehnder D., Bland R., Williams M.C., et al. Extrarenal expression of 25-hydroxyvitamin D(3)-1a-hydroxylase. J Clin Endocrinol Metab 2001, 86:888-894.
55. Barger-Lux M.J., Heaney R.P., Lanspa S.J., Healy J.C., DeLuca H.F. An investigation of sources of variation in calcium absorption efficiency. J Clin Endocrinol Metab 1995, 80:406-411.
56. Young M.V., Schwartz G.G., Wang L., et al. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D. Carcinogenesis 2004, 25:967-971.
57. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res 2003, 164:29-42.
58. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signaling Pathways in Cancer: potential for Ani-cancer therapeutics. Nature Rev 2007, 7:684-700.
59. Bhatia M., Kirkland J.B., Meckling-Gill K.A. Monocytic Differentiation of acute promyelocytic leukemia cells in response to 1,25-dihydroxyvitamin D3 is independent of nuclear receptor binding. J Biol Chem 1995, 270:15962-15965.
60. Hardman W.E. Omega-3 fatty acids to augment cancer therapy. J Nutr 2002, 132:3508S-3512S.
61. Roynette C.E., Calder P.C., Dupertuis Y.M., Pichard C. N-3 Polyunsaturated fatty acids and colon cancer prevention. Clin Nutr 2004, 23:139-151.
62. Haag M., Magada O.N., Claassen N., Bohmer L.H., Kruger M.C. Omega-3 fatty acids modulate ATPases involved in duodenal Ca absorption. Prostaglan leukotrienes Essent Fatty Acids 2003, 68(6):423-429.
63. Xue L., Lipkin M., Newmark H., Wang J. Influence of dietary calcium and vitamin D on diet-induced epithelial cell hyperproliferation in mice. J Natl Cancer Inst 1999, 91:176-181.
64. Haag M., Kruger M.C. Upregulation of duodenal calcium absorption by poly-unsaturated fatty acids: events at the basolateral membrane. Med Hypotheses 2001, 56:637-640.
65. Nemere I., Campbell K. Immunochemical studies on the putative plasmalemmal receptor for 1, 25-dihydroxyvitamin D3. III. Vitamin D status. Steroids 2000, 65:451-457.
66. Claassen N., Coetzer H., De Winter R., Haag M., Kruger M.C. Relationship between duodenal calcium uptake and Ca2+-Mg2+-ATPase activity. Med Sci Res 1996, 24:809-811.
67. Jack-Hays M.G., Xie Z., Wang Y., Huang W.H., Askari A. Activation of Na+/K+-ATPase by fatty acids, acylglycerols, and related amphipiles: structure-activity relationship. Biochim Biophys Acta 1996, 279:43-48.
68. Niggli V., Adunyah E.S., Carafoli E. Acidic phospholipids, unsaturated fatty acids and limited proteolysis mimic the effect of calmodulin on the purified erythrocyte Ca2+-ATPase. J Biol Chem 1981, 256:8588-8592.
69. Watson A. An overview of apoptosis and the prevention of colorectal cancer. Crit Rev Oncol Hematol 2006, 57:107-121.
70. Schmitt C.A., Fridman J.S., Yang M., Baranov E., Hoffman R.M., Lowe S.W. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell 2002, 1:289-298.
71. Kim H., Vosseler C.A., Weber P.C., Erl W. Docosahexaenoic acid induces apoptosis in proliferating human endothelial cells. J Cell Physiol 2005, 204(3):881-888.
72. Maruyama R., Aoki F., Toyota M., et al. Comparative genome analysis identifies the vitamin D receptor gene as a direct target of p53-mediated transcriptional activation. Cancer Res 2006, 66:4574-4583.
73. Lambert J.R., Kelly J.A., Shim M., et al. Prostate derived factor in human prostate cancer cells: gene induction by vitamin D via a p53-dependent mechanism and inhibition of prostate cancer cell growth. J Cell Physiol 2006, 208:566-574.
74. Ylikomi T., Laaksi I., Lou Y.R., et al. Antiproliferative action of vitamin D. Vitamins Hormones 2002, 64:357-406.
75. Diaz G.D., Paraskeva C., Thomas M.G., Binderup L., Hague A. Apoptosis is induced by the active metabolite of Vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res 2000, 60:2304-2312.
76. Narayanan B.A., Narayanan N.K., Reddy B.S. Docosahexaenoic acid regulated genes and transcription factors inducing apoptosis in human colon cancer cells. Int J Oncol 2001, 19:1255-1262.
77. Kim J., Na H.K., Pak Y.K., et al. Roles of ERK and p38 mitogen-activated protein kinases in phorbol ester-induced NF-kappaB activation and COX-2 expression in human breast epithelial cells. Chem Biol Interact 2008, 171(2):133-141.
78. Roux P.P., Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004, 68:320-344.
79. Guan Z., Buckman S.Y., Pentland A.P., Templeton D.J., Morrison A.R. Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4 → p38 mitogen-activated protein kinase pathway. J Biol Chem 1998, 273:12901-12908.
80. Rose D.P., Connolly J.M. Omega-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 1999, 83:217-244.
81. Krishnan A., Moreno J., Nonn L., et al. Novel pathways that contribute to the anti-proliferative and chemopreventive activities of calcitriol in prostate cancer. J Steroid Biochem Mol Biol 2007, 103(3-5):694-702.
82. Michalaki V., Syrigos K., Charles P., Waxman J. Serum levels of IL-6 and TNF-a correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer 2004, 90:2312-2316.
83. Nagpa S., Na S., Rathnachalan R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005, 26:662-687.
84. Meckling KA. Nutrient and Phytochemical Modulation of Cancer Therapy. In: Meckling KA, editor. Nutrient-Drug Interactions, Boca Raton, FL, USA: Taylor and Francis, Publishers;2007, p. 108-113.
85. Bonizzi G., Karin M. The two NF-kappaB activation pathwaysand their role in innate and adaptive immunity. Trends Immunol 2004, 25:280-288.
86. Adorini L., Penna G., Giarratana N., et al. Dendritic cells as key targets for immunomodulation by vitamin D receptor ligands. J Steroid Biochem Mol Biol 2004, 89-90:437-441.
87. Wu W., Beilhartz G., Roy Y., et al. Nuclear translocation of the 1,25D3-MARRS (membrane associated rapid response to steroids) receptor protein and NFkappaB in differentiating NB4 leukemia cells. Exp Cell Res 2010, 316:1101-1108.
88. Diaz O., Berquand A., Dubois M., et al. The mechanism of docosahexaenoic acid-induced phospholipase D activation in human lymphocytes involves exclusion of the enzyme from lipid rafts. J Biol Chem 2002, 277:39368-39378.
89. Ma D.W., Seo J., Switzer K.C., et al. N-3 PUFA and membrane microdomains: a new frontier in bioactive lipid research. J Nutr Biochem 2004, 15:700-706.
90. Baracos V.E., Mazurak V.C., Ma D.W. N-3 Polyunsaturated fatty acids throughout the cancer trajectory: influence on disease incidence, progression, response to therapy and cancer-associated cachexia. Nutr Res Rev 2004, 17:177-192.
91. Mathieu C., Gysemans C., Giulietti A., Bouillon R. Vitamin D and diabetes. Diabetologica 2005, 48:1247-1257.
92. Schmidt E.B., Pedersen J.O., Ekelund S., Grunnet N., Jersild C., Dyerberg J. Cod liver oil inhibits neutrophil and monocyte chemotaxis in healthy males. Atherosclerosis 1989, 77(1):53-57.
93. Lindquist J.A., Hammerling G., Trowsdale J. ER60/ERp57 forms disulfide-bonded intermediates with MHC class I heavy chain. FASEB 2001, 15:1448-1450.
94. Garbi N., Hammerling G., Tanaka S. Interaction of ERP57 and tapasin in the generation of MHC class I-peptide complexes. Curr Opinions Immunol 2007, 19:99-105.
95. McCarty M.F. Fish oil may impede tumour angiogenesis and invasiveness by down-regulating protein kinase C and modulating eicosanoid production. Med Hypotheses 1996, 46:107-115.
96. Form D.M., Auerbach R. PGE2 and angiogenesis. Proc Soc Exp Biol Med 1983, 172:214-218.
97. Bao B.Y., Yao J., Lee Y.F., et al. 1α25-dihydroxyvitamin D3 supresses interleukin-8 mediated prostate cancer cell angiogenesis. Carcinogenesis 2006, 27:1883-1893.
98. Krishnan A.V., Shinghal R., Raghavachari N., Brooks J.D., Peehl D.M., Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 2004, 59:243-251.
99. White J.H. Profiling 1, 25-dihydroxyvitamin D-regulated gene expression by microarray analysis. J Steroid Biochem Mol Bio 2004, 89(/90):239-244.
100. Fan Y.Y., Spencer T.E., Wang N., Moyer M.P., Chapkin R.S. Chemopreventive n-3 fatty acids activate RXR alpha in colonocytes. Carcinogenesis 2003, 24(9):1541-1548.
101. Mehta R. Vitamin D and cancer. J Nut Biochem 2002, 13(5):252.
102. Baran D. Annexin II is the membrane receptor that mediates the rapid actions of 1α, 25-dihydroxyvitamin D3. J Cell Biochem 2000, 78(1):34.
103. Huhtakangas J.A., Olivera C.J., Bishop J.E., Zanello L.P., Norman A.W. The Vitamin D Receptor Is Present in Caveolae- Enriched Plasma Membranes and Binds 1,25(OH)2Vitamin D3 in Vivo and in Vitro. Mol Endocrinol 2004, 18(11):2660-2671.
104. Brown D.A., London E. Functions of lipid rafts in biological membranes. Annu Rev Cell Dev Biol 1998, 14:111-136.
105. Boyan B. Membrane actions of vitamin D metabolites 1α, 25(OH)2D3 and 24R, 25(OH)2D3 are retained in growth plate cartilage cells from vitamin D receptor knockout mice. J Cell Biochem 2003, 90(6):1207.
106. Sylvia V.L., Schwartz Z., Curry D.B., Chang Z., Dean D.D., Boyan B.D. 1, 25-(OH)2D3 regulates protein kinase C activity through two phospholipid-independent pathways involving phospholipase A2 and phospholipase C in growth zone chondrocytes. J Bone Miner Res 1998, 13:559-569.
107. Schwartz Z., Ehland H., Sylvia V.L., Larsson D., Bingham V., Hardin R.R., et al. 1a, 25(OH)2D3 and 24R, 25(OH)2D3 modulate growth plate chondrocyte physiology via PKC-dependent phosphorylation of ERK1/2 MAP kinase. Endocrinology 2002, 143:2775-2786.
108. Tunsophon S., Nemere I. Protein kinase C isotypes in signal transduction for the 1,25D3-MARRS receptor (ERp57/PDIA3) in steroid hormone-stimulated phosphate. Steroids 2010, 75(4-5):307-313.
109. Berry D.M., Antochi R., Bhatia M., Meckling-Gill K.A. 1,25-Dihydroxyvitamin D3 stimulates expression and translocation of protein kinase Calpha and Cdelta via a nongenomic mechanism and rapidly induces phosphorylation of a 33-kDa protein in acute promyelocytic NB4 cells. J Biol Chem 1996, 271(27):16090-16096.
110. Pandian S.S., et al. Fatty acid regulation of protein kinase C isoforms in prostate cancer cells. Biochem Biophys Res Commun 2001, 283:806-812.
111. O'Brian C.A., Vogel V.G., Singletary S.E., Ward N.E. Elevated protein kinase C expression in human breast tumour biopsies relative to normal breast tissue. Cancer Res 1989, 49:3215-3217.
112. Hirai M., Gamou S., Kobayashi M., Shimizu N. Lung cancer cells often express high levels of protein kinase C activity. Jpn J Cancer Res 1989, 80:204-208.
113. Pongracz J., Clark P., Neoptolemos J.P., Lord J.M. Expression of protein kinase C isoenzymes in colorectal cancer tissue and their differential activation by different bile acids. Int J Cancer 1995, 61:35-39.
114. Richard C.L., Farach-Carson M.C., Rohe B., Nemere I., Meckling K. A involvement of 1,25D3-MARRS (Membrane Associated Rapid Response to Steroids), a novel vitamin D receptor, in 1,25(OH)2D3-induced growth inhibition of breast cancer. Exp Cell Res 2010, 316:695-703.
115. Swinnen J.V., Van Veldhoven P.P., Timmermans L., De Schrijver E., Brusselmans K., Vanderhoydonc F., et al. Biochem Biophys Res Commun 2003, 302(4):898.
116. Schley P.D., Brindley D.N. Field CJ (n-3) PUFA alter raft lipid composition and decrease epidermal growth factor receptor levels in lipid rafts of human breast cancer cells. J Nutr 2007, 137:548-553.
117. Bougnoux P., et al. Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br J Cancer 2009, 101(12):1978-1985.
118. Bougnoux P., Chajès V., Germain E., Hubert B., Lhuillery C., Le Floch O., et al. Cytotoxic drug efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma. Br J Cancer 1999, 79(11-12):1765-1769.
119. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res 2001, 3:323-327.
120. Feinendegen L.E. Reactive oxygen species in cell responses to toxic agents. Hum Exp Toxicol 2002, 21:85-90.